Drug Profile
Osilodrostat - Recordati
Alternative Names: Isturisa; LCI-699Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Recordati
- Class Antihypertensives; Antineoplastics; Antisecretories; Corticosteroids; Fluorobenzenes; Heart failure therapies; Imidazoles; Nitriles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Aldosterone synthase inhibitors; Steroid 11-beta-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cushing syndrome; Pituitary ACTH hypersecretion
- Discontinued Heart failure; Hypertension; Solid tumours
Most Recent Events
- 15 Jun 2023 Pooled efficacy and adverse events data from the phase III LINC-3 and LINC-4 trials in Cushing's Disease presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
- 31 Aug 2022 Efficacy and adverse events data from the phase III LINC 3 trial in Cushings disease released by Recordati
- 15 Jun 2022 Efficacy and adverse events data from a phase III Linc 3 and Linc 4 trial in Cushing’s disease presented at the 104th Annual Meeting of the Endocrine Society (ENDO-2022)